Salim Ben Yahia, Bechir Jelliti, Rim Kahloun, Rim Ghrissi, Salah Jenzeri, Moncef Khairallah (Monastir, Tunisia)

Advantages:

To manage inflammatory choroidal neovascularization (CNV) with intravitreal injection of bevacizumab, since conventional therapeutic options, including laser photocoagulation, surgery, corticosteroids, and verteporfin therapy, have potential limitations and are associated with a high rate of recurrences.

Methods:

Three eyes of 3 young patients with inflammatory CNV were treated with a single intravitreal injection of 1.25 mg (0.05 mL) of bevacizumab. CNV was secondary to ocular toxoplasmosis in 2 patients and to pseudohistoplasmosis in one patient. Main outcome measures included changes in best-corrected visual acuity, central foveal thicknesses measured by optical coherence tomography, and leakage on fluorescein angiography. Follow-up was at least 12 months.

Effectiveness / Safety:

Complete closure of CNV occurred in all treated eyes, within the first 6 weeks of treatment, with subsequent improvement of visual acuity. No recurrence of CNV and no ocular or systemic side effects were observed during the follow-up period.

Take home message:

A single intravitreal injection of bevacizumab appears to be an effective and safe treatment modality for inflammatory CNV.